{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0009725\nAge: 67\nGender: Female\nSample ID: P-0009725-T01-IM5\nGene Panel: IMPACT410\nCancer Type: Breast Invasive Ductal Carcinoma\nSample Type: Metastasis\nTumor Purity: 20.0%\n=============\nDNA Variants:\nARAF c.1385C>T (p.P462L) - in 19.00% of 1430 reads\nBAP1 c.1414G>A (p.G472R) - in 18.00% of 1734 reads\nMYCN c.340G>A (p.D114N) - in 14.00% of 521 reads\nPIK3CA c.1035T>A (p.N345K) - in 32.00% of 625 reads\nTP53 c.659A>G (p.Y220C) - in 26.00% of 1117 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Breast Invasive Ductal Carcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Alpelisib (PI3K alpha inhibitor)\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified\",\n    \"Genomic Features\": \"PIK3CA c.1035T>A (p.N345K)\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209944s000lbl.pdf\"\n  }\n}"
}